Dosing & Uses
Dosage Forms & Strengths
transdermal gel injection
intraocular injection solution
Osteoarthritis of Knee
Indicated for treatment of pain in osteoarthritis of the knee
Administer by intra-articular injection into the affected knee(s)
Euflexxa: Inject 20 mg (2 mL) qWeek for 3 weeks
Hyalgan: Inject 20 mg (2 mL) qWeek for 3-5 weeks
Supartz: Inject 25 mg (2.5 mL) qWeek for 5 weeks
- Concomitant use of disinfectants containing quaternary ammonium salts (eg, benzalkonium chloride) for skin preparation can precipitate in presence of hyaluronic acid
- Use strict aseptic injection technique
- Inject the full contents of single syringe into 1 knee only; if treatment is bilateral, a separate syringe should be used for each knee
Ophthalmic Viscoelastic Devices (OVDs)
Surgical aid to protect corneal endothelium during anterior segment and vitreous procedures (eg, cataract extraction, intraocular lens implantation, corneal transplant, glaucoma filtration, retinal attachment surgery)
AMO Vitrax, Amvisc, Amvisc Plus, Healon, Healon GV, Healon5: Inject sufficient amount slowly (using cannula or needle) into anterior chamber or vitreous cavity of eye; some procedures/products require removal of the sodium hyaluronate following surgical completion
Skin Ulcers and Wounds
Cream: Apply a thin layer to wound or ulcer that have been cleaned and desinfected
Gel: Apply liberally once daily to ulcer cavity or wound and surrounding areas
<21 years: Safety and efficacy not established
>21 years: 1.5 mL per lip (upper or lower) per treatment session
Safety & efficacy not established
- Erythema (75-93%)
- Swelling (91-03%)
- Tenderness (61-92%)
- Lumps/bumps (56-83$)
- Discoloration (33-78%)
- Pruritus (25-36%)
Increased blood pressure (4%)
Pain at injection site (intra-articular) (3%)
Limb pain (2%)
Frequency Not Defined
- Injection site pain
- Anaphylactoid reaction
- Increased IOP
- Cystoid macular edema
- Conjunctival hemorrhage
- Hypersensitivity to hyaluronate preparations, avian-derived products (eg, eggs, feathers, poultry), gram-positive bacterial proteins
- Do not inject in knees with infection or skin diseases in area of injection site or joint
- No known contraindications
- Transient increased inflammation in injected knee may occur
- Avoid strenuous activity or prolonged (>1 hr) weight-bearing activities (eg, running, tennis) within 48 hr following injection
- Pain relief may not be evident until after 3rd injection
- Remove joint effusion, if present, before injection
- Use only if solution is clear
- Monitor intraocular pressure
Pregnancy & Lactation
Pregnancy Category: N/A
Lactation: Not known if excreted in breast milk; not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Sodium hyaluronate and its derivatives form a viscoelastic solution in water suitable for aqueous and vitreous humor in ophthalmic surgery; works as a lubricant, which plays an important role in managing interactions between adjacent tissues
Protects sking against friction and abrassion in the management of wounds and ulcers
Distribution: Slow (intravitreous injection)
Excretion: Canal of Schlemm (ophthalmic)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs